Koriokarsinoma
Published on May 17, 2026
Risk Factors
Prior complete hydatidiform mole (highest risk), prior partial mole, ectopic pregnancy, spontaneous or therapeutic abortion, normal pregnancy (rare). Extremes of reproductive age.
Etiology
Malignant proliferation of trophoblastic tissue (both cytotrophoblast and syncytiotrophoblast) without formation of chorionic villi. Most cases arise after a molar pregnancy, but any gestational event can precede it.
Presentation
Persistent or rising beta-hCG after evacuation of a molar pregnancy. Irregular vaginal bleeding weeks to months after any gestational event. May present with symptoms from metastatic disease (hemoptysis, neurological deficits, hepatic pain).
Classic Exam
Enlarged, boggy uterus. Irregular vaginal bleeding. Theca lutein cysts may persist bilaterally. Signs of distant metastasis on presentation (lungs most common).
Diagnostics
Persistently elevated or rising serum beta-hCG after molar evacuation. Pelvic ultrasound showing heterogeneous uterine mass with increased vascularity. Chest X-ray showing "cannonball" metastases. Tissue biopsy (when available) shows sheets of malignant trophoblast without villi.
Management
Single-agent chemotherapy (methotrexate or actinomycin D) for low-risk disease. Multi-agent chemotherapy (EMA-CO regimen) for high-risk or metastatic disease. Hysterectomy may be adjunctive in select cases. Serial beta-hCG monitoring until undetectable, then monthly surveillance for 12 months.
Keywords
"Rising beta-hCG after molar evacuation," "no chorionic villi on histology," "cannonball metastases," "hemorrhagic mass," "absent villi," "highly chemo-sensitive"
01Pathophysiology
Choriocarcinoma is the most aggressive form of gestational trophoblastic neoplasia (GTN). It arises from malignant transformation of trophoblastic tissue, involving both the cytotrophoblast and the syncytiotrophoblast. The hallmark histological finding is sheets of anaplastic trophoblastic cells without the formation of chorionic villi. This absence of villi is the defining feature that separates choriocarcinoma from a hydatidiform mole, where villi are present but abnormal.
The syncytiotrophoblast normally produces beta-hCG during pregnancy. Because choriocarcinoma is composed of malignant trophoblastic cells that retain this secretory function, serum beta-hCG levels are markedly elevated and serve as a reliable tumor marker. The degree of elevation often correlates with tumor burden, and a rising or plateauing beta-hCG after evacuation of a mole is the clinical trigger that defines progression to GTN.
Choriocarcinoma is characterized by early hematogenous spread. The tumor has a strong tendency to invade blood vessels, which explains both the hemorrhagic nature of the primary uterine lesion and the pattern of distant metastasis. The lungs are the most common site of metastatic disease (approximately 80% of metastatic cases), followed by the vagina, liver, and brain. Pulmonary involvement can manifest as hemoptysis or dyspnea, and the classic radiographic appearance is bilateral "cannonball" lesions on chest X-ray.
The reason this tumor follows a molar pregnancy more often than a normal pregnancy is tied to the biology of the mole itself. A complete hydatidiform mole carries the highest risk of malignant transformation (15 to 20%) because the entire genetic material is paternal in origin (androgenetic), creating a trophoblastic environment that is inherently more proliferative and prone to neoplastic change. However, it is critical to remember that choriocarcinoma can follow any gestational event, including term pregnancies, ectopic pregnancies, and abortions.
Despite its aggressive biology, choriocarcinoma is one of the most chemo-sensitive solid tumors in oncology. Even widely metastatic disease, including brain metastases, can be cured with appropriate chemotherapy. This is a frequently tested concept: the prognosis of choriocarcinoma is excellent when treated, which contrasts sharply with its histological aggressiveness.
02Classification and Clinical Manifestation
Choriocarcinoma is classified under the broader category of gestational trophoblastic neoplasia. The FIGO staging system combined with the WHO prognostic scoring system is used to categorize patients into low-risk and high-risk groups, which directly determines treatment.
FIGO Anatomic Staging
Stage | Description |
|---|---|
I | Disease confined to the uterus |
II | Disease extends to other genital structures (vagina, adnexa, broad ligament) |
III | Disease extends to the lungs, with or without genital tract involvement |
IV | All other metastatic sites (brain, liver, kidney, gastrointestinal tract) |
WHO Prognostic Scoring System
This scoring system assigns points based on prognostic variables. A total score of 6 or less is classified as low risk, and 7 or more is classified as high risk.
Age
0 Points
< 40
1 Point
40 or older
2 Points
4 Points
Antecedent pregnancy
0 Points
Mole
1 Point
Abortion
2 Points
Term pregnancy
4 Points
Interval from index pregnancy
0 Points
< 4 months
1 Point
4 to 6 months
2 Points
7 to 12 months
4 Points
> 12 months
Pretreatment beta-hCG (IU/L)
0 Points
< 1,000
1 Point
1,000 to 10,000
2 Points
10,000 to 100,000
4 Points
> 100,000
Largest tumor size
0 Points
< 3 cm
1 Point
3 to 4 cm
2 Points
5 cm or more
4 Points
Site of metastases
0 Points
Lung
1 Point
Spleen, kidney
2 Points
GI tract
4 Points
Brain, liver
Number of metastases
0 Points
0
1 Point
1 to 4
2 Points
5 to 8
4 Points
> 8
Prior failed chemotherapy
0 Points
1 Point
2 Points
Single drug
4 Points
Two or more drugs
Prognostic Factor | 0 Points | 1 Point | 2 Points | 4 Points |
|---|---|---|---|---|
Age | < 40 | 40 or older | ||
Antecedent pregnancy | Mole | Abortion | Term pregnancy | |
Interval from index pregnancy | < 4 months | 4 to 6 months | 7 to 12 months | > 12 months |
Pretreatment beta-hCG (IU/L) | < 1,000 | 1,000 to 10,000 | 10,000 to 100,000 | > 100,000 |
Largest tumor size | < 3 cm | 3 to 4 cm | 5 cm or more | |
Site of metastases | Lung | Spleen, kidney | GI tract | Brain, liver |
Number of metastases | 0 | 1 to 4 | 5 to 8 | > 8 |
Prior failed chemotherapy | Single drug | Two or more drugs |
Clinical Manifestation
Presentation | Clinical Features |
|---|---|
Post-molar (most common) | Persistent vaginal bleeding after molar evacuation, failure of beta-hCG to normalize on serial monitoring, enlarged uterus |
Post-pregnancy or post-abortion | Irregular vaginal bleeding weeks to months after the event, positive pregnancy test with no intrauterine pregnancy on ultrasound |
Metastatic presentation | Hemoptysis or dyspnea (pulmonary), headache or seizures or focal neurological deficits (cerebral), right upper quadrant pain (hepatic), vaginal nodules that bleed easily |
03Diagnostic Workup
Serial serum beta-hCG
Role
Best initial test and primary surveillance tool
Key Findings
Rising, plateauing, or persistently elevated after molar evacuation. Criteria for GTN: plateau over 4 values across 3 weeks, or rise over 3 values across 2 weeks, or persistence at 6 months
Pelvic ultrasound
Role
Evaluate uterine involvement
Key Findings
Heterogeneous, hypervascular uterine mass, often with areas of hemorrhage and necrosis. No "snowstorm" pattern (that suggests mole)
Chest X-ray
Role
Screen for pulmonary metastasis
Key Findings
Bilateral "cannonball" lesions or diffuse nodular infiltrates
CT chest (if CXR abnormal)
Role
Further characterize pulmonary disease
Key Findings
Better sensitivity for small metastatic nodules
CT or MRI of abdomen and pelvis
Role
Staging for extent of disease
Key Findings
Evaluate liver, pelvic soft tissue involvement
MRI brain
Role
Required if high-risk score or Stage IV suspected
Key Findings
Hemorrhagic brain metastases with surrounding edema
Histopathology
Role
Confirmatory (when tissue is available)
Key Findings
Biphasic pattern of malignant cytotrophoblast and syncytiotrophoblast, extensive hemorrhage and necrosis, absence of chorionic villi
Test | Role | Key Findings |
|---|---|---|
Serial serum beta-hCG | Best initial test and primary surveillance tool | Rising, plateauing, or persistently elevated after molar evacuation. Criteria for GTN: plateau over 4 values across 3 weeks, or rise over 3 values across 2 weeks, or persistence at 6 months |
Pelvic ultrasound | Evaluate uterine involvement | Heterogeneous, hypervascular uterine mass, often with areas of hemorrhage and necrosis. No "snowstorm" pattern (that suggests mole) |
Chest X-ray | Screen for pulmonary metastasis | Bilateral "cannonball" lesions or diffuse nodular infiltrates |
CT chest (if CXR abnormal) | Further characterize pulmonary disease | Better sensitivity for small metastatic nodules |
CT or MRI of abdomen and pelvis | Staging for extent of disease | Evaluate liver, pelvic soft tissue involvement |
MRI brain | Required if high-risk score or Stage IV suspected | Hemorrhagic brain metastases with surrounding edema |
Histopathology | Confirmatory (when tissue is available) | Biphasic pattern of malignant cytotrophoblast and syncytiotrophoblast, extensive hemorrhage and necrosis, absence of chorionic villi |
Pelvic ultrasound with Doppler is the best initial imaging study to evaluate the uterine component. The tumor appears as a heterogeneous mass with prominent blood flow, reflecting its hemorrhagic and highly vascular nature. This is distinct from the classic "snowstorm" or "cluster of grapes" pattern seen in a hydatidiform mole, which has already been evacuated by this point.
A chest X-ray is performed in all patients because the lungs are the most frequent site of metastasis. The classic finding is bilateral, well-circumscribed "cannonball" lesions, though smaller nodular opacities or even a miliary pattern can occur. If the chest X-ray is abnormal, CT of the chest is obtained for better characterization and to quantify the number and size of metastases for staging purposes.
MRI of the brain is indicated when the WHO prognostic score is high or when there is any neurological symptom. Brain metastases from choriocarcinoma are characteristically hemorrhagic, which is a high-yield imaging pearl. A beta-hCG ratio between serum and cerebrospinal fluid can also be used to detect occult central nervous system involvement (a CSF-to-serum ratio greater than 1:60 suggests CNS disease).
When histological tissue is obtained (e.g., from hysterectomy or curettage), the confirmatory finding is the absence of chorionic villi with sheets of malignant trophoblast. This is the single most important histological discriminator from a hydatidiform mole.
04Management and Treatment
Low-risk GTN (score 0 to 6)
Treatment
Single-agent chemotherapy
Details
Methotrexate 1 mg/kg IM on days 1, 3, 5, 7 with folinic acid rescue 0.1 mg/kg on days 2, 4, 6, 8 (8-day regimen), repeated every 2 weeks. Alternative: Actinomycin D 1.25 mg/m2 IV every 2 weeks (pulse dosing).
High-risk GTN (score 7 or more)
Treatment
Multi-agent chemotherapy
Details
EMA-CO regimen: Etoposide, Methotrexate, Actinomycin D alternating with Cyclophosphamide and Vincristine (Oncovin). Administered in alternating weekly cycles.
Brain metastases
Treatment
EMA-CO with modifications
Details
High-dose methotrexate (1 g/m2 in the EMA component) to achieve CNS penetration. Intrathecal methotrexate may be added. Whole-brain radiation in select cases.
Resistant or relapsed disease
Treatment
Salvage regimens
Details
EMA-EP (Etoposide and Cisplatin replacing CO) or other platinum-based combinations.
Adjunctive hysterectomy
Treatment
Selected patients
Details
Considered if disease is confined to the uterus in patients who have completed childbearing, or for heavy uncontrolled uterine bleeding. Does not replace chemotherapy.
Clinical Scenario | Treatment | Details |
|---|---|---|
Low-risk GTN (score 0 to 6) | Single-agent chemotherapy | Methotrexate 1 mg/kg IM on days 1, 3, 5, 7 with folinic acid rescue 0.1 mg/kg on days 2, 4, 6, 8 (8-day regimen), repeated every 2 weeks. Alternative: Actinomycin D 1.25 mg/m2 IV every 2 weeks (pulse dosing). |
High-risk GTN (score 7 or more) | Multi-agent chemotherapy | EMA-CO regimen: Etoposide, Methotrexate, Actinomycin D alternating with Cyclophosphamide and Vincristine (Oncovin). Administered in alternating weekly cycles. |
Brain metastases | EMA-CO with modifications | High-dose methotrexate (1 g/m2 in the EMA component) to achieve CNS penetration. Intrathecal methotrexate may be added. Whole-brain radiation in select cases. |
Resistant or relapsed disease | Salvage regimens | EMA-EP (Etoposide and Cisplatin replacing CO) or other platinum-based combinations. |
Adjunctive hysterectomy | Selected patients | Considered if disease is confined to the uterus in patients who have completed childbearing, or for heavy uncontrolled uterine bleeding. Does not replace chemotherapy. |
Acute stabilization in a patient presenting with hemorrhage from a choriocarcinoma lesion (uterine or vaginal) involves hemodynamic resuscitation with IV fluids and blood products as needed. Vaginal metastatic nodules should not be biopsied due to risk of catastrophic bleeding. The definitive control of hemorrhage in these cases is initiation of chemotherapy, which produces rapid tumor regression.
For low-risk disease, methotrexate is the preferred first-line agent. Treatment is continued until beta-hCG is undetectable, and then an additional 2 to 3 consolidation cycles are given beyond the first normal value to ensure complete eradication. If beta-hCG plateaus or rises during methotrexate therapy, the patient is switched to actinomycin D. If single-agent therapy fails entirely, the patient is escalated to multi-agent chemotherapy (EMA-CO).
For high-risk disease, EMA-CO is the standard of care and achieves cure rates exceeding 90% even in metastatic settings. Treatment continues until beta-hCG normalizes, followed by at least 3 consolidation cycles.
After achieving undetectable beta-hCG levels, patients are monitored with monthly serum beta-hCG for 12 months (low-risk) or 24 months (high-risk). Reliable contraception is mandatory during this surveillance period to avoid confounding beta-hCG interpretation with a new pregnancy. Combined oral contraceptive pills are commonly used for this purpose.
05Differential Diagnosis and Distractors
Complete hydatidiform mole
Why It Is Similar
Elevated beta-hCG, uterine enlargement, can precede choriocarcinoma. Both involve trophoblastic proliferation.
Key Discriminator
Mole shows hydropic chorionic villi ("cluster of grapes" on gross and histology). Choriocarcinoma has no villi. Mole is managed with suction evacuation; choriocarcinoma requires chemotherapy.
Invasive mole
Why It Is Similar
Also classified as GTN. Elevated beta-hCG after molar evacuation. Can invade myometrium and metastasize.
Key Discriminator
Invasive mole retains villous structures on histology, just with myometrial invasion. Choriocarcinoma lacks villi entirely. Clinically both may be treated similarly, but the histological distinction is tested.
Placental site trophoblastic tumor (PSTT)
Why It Is Similar
Trophoblastic neoplasm, can follow any pregnancy, involves uterus.
Key Discriminator
PSTT produces relatively low beta-hCG (predominantly intermediate trophoblast, which secretes human placental lactogen rather than beta-hCG). PSTT is chemo-resistant, and hysterectomy is the primary treatment.
Ectopic pregnancy
Why It Is Similar
Positive beta-hCG, no intrauterine pregnancy on ultrasound, pelvic pain, vaginal bleeding.
Key Discriminator
Ectopic pregnancy shows an adnexal mass or tubal ring sign. Beta-hCG levels are far lower and do not rise to the extreme levels seen in choriocarcinoma. No history of prior molar pregnancy.
Retained products of conception
Why It Is Similar
Persistent bleeding and elevated beta-hCG after pregnancy.
Key Discriminator
Beta-hCG is low and declining (not rising). Ultrasound shows echogenic endometrial material without the hypervascular, heterogeneous mass pattern of choriocarcinoma.
Endometrial carcinoma
Why It Is Similar
Uterine mass, abnormal vaginal bleeding, can occur in reproductive-age women.
Key Discriminator
Beta-hCG is negative or normal. Endometrial biopsy shows glandular carcinoma, not trophoblastic tissue.
Differential Diagnosis | Why It Is Similar | Key Discriminator |
|---|---|---|
Complete hydatidiform mole | Elevated beta-hCG, uterine enlargement, can precede choriocarcinoma. Both involve trophoblastic proliferation. | Mole shows hydropic chorionic villi ("cluster of grapes" on gross and histology). Choriocarcinoma has no villi. Mole is managed with suction evacuation; choriocarcinoma requires chemotherapy. |
Invasive mole | Also classified as GTN. Elevated beta-hCG after molar evacuation. Can invade myometrium and metastasize. | Invasive mole retains villous structures on histology, just with myometrial invasion. Choriocarcinoma lacks villi entirely. Clinically both may be treated similarly, but the histological distinction is tested. |
Placental site trophoblastic tumor (PSTT) | Trophoblastic neoplasm, can follow any pregnancy, involves uterus. | PSTT produces relatively low beta-hCG (predominantly intermediate trophoblast, which secretes human placental lactogen rather than beta-hCG). PSTT is chemo-resistant, and hysterectomy is the primary treatment. |
Ectopic pregnancy | Positive beta-hCG, no intrauterine pregnancy on ultrasound, pelvic pain, vaginal bleeding. | Ectopic pregnancy shows an adnexal mass or tubal ring sign. Beta-hCG levels are far lower and do not rise to the extreme levels seen in choriocarcinoma. No history of prior molar pregnancy. |
Retained products of conception | Persistent bleeding and elevated beta-hCG after pregnancy. | Beta-hCG is low and declining (not rising). Ultrasound shows echogenic endometrial material without the hypervascular, heterogeneous mass pattern of choriocarcinoma. |
Endometrial carcinoma | Uterine mass, abnormal vaginal bleeding, can occur in reproductive-age women. | Beta-hCG is negative or normal. Endometrial biopsy shows glandular carcinoma, not trophoblastic tissue. |
06Traps and High-Yield Pearls
The most common way students miss questions on choriocarcinoma is by confusing it with a hydatidiform mole on histology-based questions. The single most important discriminator is the presence or absence of chorionic villi: moles have them, choriocarcinoma does not. If a vignette describes malignant trophoblastic tissue "without villous structures," the answer is choriocarcinoma, not mole.
Another frequent trap involves the clinical scenario of a patient with hemoptysis and a positive pregnancy test who is not currently pregnant. Students may think of pulmonary embolism, tuberculosis, or lung cancer. The key is recognizing that beta-hCG elevation in a non-pregnant woman with lung lesions should immediately raise suspicion for metastatic choriocarcinoma, and the next step is pelvic ultrasound and further beta-hCG quantification, not bronchoscopy.
Students also lose points by recommending biopsy of vaginal or uterine lesions suspected to be choriocarcinoma. These tumors are extraordinarily vascular, and biopsy can cause life-threatening hemorrhage. The diagnosis is established biochemically (serial beta-hCG) and radiographically, and treatment (chemotherapy) is initiated without tissue confirmation in most clinical scenarios.
A pearl that frequently appears: choriocarcinoma is one of the few solid malignancies where metastatic disease is still curable. Even with lung and brain metastases, cure rates with multi-agent chemotherapy remain above 80 to 90%. This contrasts with the intuition that "Stage IV cancer equals poor prognosis," and test-writers exploit this assumption.
Finally, remember the surveillance timeline. After achieving undetectable beta-hCG, monitoring continues monthly. Pregnancy must be avoided during this period because a new pregnancy would produce beta-hCG and make it impossible to detect early recurrence. The contraceptive of choice during surveillance is oral contraceptive pills, which also suppress ovulation and reduce the chance of a new molar pregnancy.